Literature DB >> 27842801

Liver involvement in Gaucher disease - Review and clinical approach.

Tomer Adar1, Yaron Ilan2, Deborah Elstein3, Ari Zimran3.   

Abstract

Gaucher disease (GD), one of the most prevalent lysosomal storage diseases, is associated with glucocerebroside accumulation in cells of the monocyte-macrophage system in various organs, including the liver. Evaluating and managing liver disease in patients with Gaucher disease may be challenging. While hepatic involvement is common in Gaucher disease, its severity, and clinical significance span a wide spectrum, ranging from sub-clinical involvement to liver cirrhosis with its associated complications including portal hypertension. Apart from liver involvement in Gaucher disease, patients with may also suffer from other comorbidities involving the liver. That Gaucher disease itself can mimic hepatic lesions, affect laboratory tests used to characterize liver disease, and may be associated with non-cirrhotic portal hypertension, complicates the diagnostic approach even more. Better understanding of liver involvement in Gaucher disease can spare patients unnecessary invasive testing, and assist physicians in decision making when evaluating patients with Gaucher disease suspected for significant liver disease. This review describes the various clinical manifestations, laboratory and imaging abnormalities that may be encountered when following patients with Gaucher disease for liver involvement. The mechanism for liver disease are discussed, as well as the possible hepato-protective effect of glucocerebroside, and the a diagnostic and treatment approaches.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gaucher disease; Liver disease

Mesh:

Substances:

Year:  2016        PMID: 27842801     DOI: 10.1016/j.bcmd.2016.10.001

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  6 in total

1.  ACE phenotyping in Gaucher disease.

Authors:  Sergei M Danilov; Victoria E Tikhomirova; Roman Metzger; Irina A Naperova; Tatiana M Bukina; Ozlem Goker-Alpan; Nahid Tayebi; Nurshat M Gayfullin; David E Schwartz; Larisa M Samokhodskaya; Olga A Kost; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2018-02-17       Impact factor: 4.797

Review 2.  Lipids: biomarkers of healthy aging.

Authors:  I Almeida; S Magalhães; A Nunes
Journal:  Biogerontology       Date:  2021-04-10       Impact factor: 4.277

Review 3.  Molecular regulations and therapeutic targets of Gaucher disease.

Authors:  Yuehong Chen; Neetu Sud; Aubryanna Hettinghouse; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2018-04-11       Impact factor: 7.638

Review 4.  Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement.

Authors:  Andrew J Degnan; Victor M Ho-Fung; Rebecca C Ahrens-Nicklas; Christian A Barrera; Suraj D Serai; Dah-Jyuu Wang; Can Ficicioglu
Journal:  Insights Imaging       Date:  2019-07-10

5.  Liver involvement in patients with Gaucher disease types I and III.

Authors:  Rodrigo Tzovenos Starosta; Filippo Pinto E Vairo; Alícia Dorneles Dornelles; Suélen Porto Basgalupp; Marina Siebert; Maria Lúcia Alves Pedroso; Carlos Thadeu Schmidt Cerski; Mário Reis Álvares-da-Silva; Ida Vanessa Doederlein Schwartz
Journal:  Mol Genet Metab Rep       Date:  2020-01-07

6.  Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites in Gaucher Disease.

Authors:  Kunal Adhyaru; Sherna Menezes; Pramod K Mistry; Aabha Nagral
Journal:  Cureus       Date:  2022-04-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.